Horta-Baas G, Sandoval-Cabrera A, Romero-Figueroa M. Modification of Gut Microbiota in Inflammatory Arthritis: Highlights and Future Challenges[J]. Curr Rheumatol Rep, 2021, 23(8): 67.
[2]
Zhang S, Zeng B, Chen Y, et al. Gut microbiota in healthy and unhealthy long-living people[J]. Gene, 2021,779(1):145510.
[3]
Manasa J S. Role of the normal gut microbiota[J]. World J Gastroenterology, 2015(29):17.
[4]
Gomes A C, Hoffmann C, Mota J O F. The human gut microbiota: metabolism and perspective in obesity[J]. Gut Microbes, 2018,9(4):308-325.
[5]
Stephen M, David L S, Christopher J D. The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions[J]. Ther Adv Gastroenter, 2016, 9(4):606-25.
[6]
Lee M, Chang E B. Inflammatory bowel diseases (IBD) and the microbiome-searching the crime scene for clues[J]. Gastroenterology, 2021,160(2):524-537.
[7]
Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis[J]. Gut, 2014, 63(8): 1275-1283.
[8]
Stinson L F, Payne M S, Keelan J A. Planting the seed: origins, composition, and postnatal health significance of the fetal gastrointestinal microbiota[J]. Crit Rev Microbiol, 2017, 43(3): 352-369.
[9]
Dixon L J, Amrita K, Nickerson K P, et al. Combinatorial effects of diet and genetics on inflammatory bowel disease pathogenesis[J]. Inflamm Bowel Dis, 2015, 21(4): 912-922.
[10]
Adolph T E, Zhang J. Diet fuelling inflammatory bowel diseases: preclinical and clinical concepts[J]. Gut, 2022,71(12):2574-2586.
[11]
Long M, Ponder. A clinical review of recent findings in the epidemiology of inflammatory bowel disease[J]. Clin Epidemiol, 2013, 5(1): 237-247.
[12]
Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: current perspectives[J]. World J Gastroenterology, 2023, 29(14): 2078-2100.
[13]
Sakamoto N, Kono S, Wakai K, et al. Dietary risk factors for inflammatory bowel disease a multicenter case-control study in Japan[J]. Inflamm Bowel Dis, 2005, 11(2):154-163.
[14]
Lane E R, Timothy Z, David S. The microbiota in inflammatory bowel disease: current and therapeutic insights[J]. J Inflamm Res, 2017, 10: 63-73.
[15]
Ronan T, Franois B, Béatrice D, et al. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency[J]. Inflamm Bowel Dis, 2010(4): 684-695.
[16]
Ranjbar R, Vahdati S N, Tavakoli S, et al. Immunomodulatory roles of microbiota-derived short-chain fatty acids in bacterial infections[J]. Biomed Pharmacother, 2021,141(1):111817.
[17]
Brown E M, Sadarangani M, Finlay B B. The role of the immune system in governing host-microbe interactions in the intestine[J]. Nat Immunol, 2013, 14(7): 205.
[18]
Kinnebrew M A, Buffie C G, Diehl G E, et al. Interleukin 23 production by intestinal CD103(+)CD11b(+) dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense[J]. Immunity, 2012, 36(2): 276-287.
[19]
Dalile B, Oudenhove L V, Vervliet B, et al. The role of short-chain fatty acids in microbiota–gut–brain communication[J]. Nat Rev Gastro Hepat, 2019, 16(8): 461-478.
[20]
Kamada N, Kim Y G, Sham H P, et al. Regulated virulence controls the ability of a pathogen to compete with the gut microbiota[J]. Science, 2012, 336(6086):1325-1329.
[21]
Cai J, Sun L, Gonzalez F J. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis[J]. Cell Host Microbe, 2022, 30(3):289-300.
[22]
Hou Q, Ye L, Liu H, et al. Lactobacillus accelerates ISCs regeneration to protect the integrity of intestinal mucosa through activation of STAT3 signaling pathway induced by LPLs secretion of IL-22[J]. Cell Death Differ, 2018, 28(6): 2025-2027.
[23]
Erny D, de Angelis A L H, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS[J]. Nat Neurosci,2015,18(7): 965-977.
[24]
Hsiao E Y, Mcbride S W, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders[J]. Cell, 2013, 155(7): 1451-1463.
[25]
Wang H, Braun C, Murphy E F, et al. Bifidobacterium longum 1714 strain modulates brain activity of healthy volunteers during social stress[J]. Am J Gastroenterol,2019,114(7):1152-1162.
[26]
Masanetz R K, Winkler J, Winner B, et al. The gut-immune-brain axis: an important route for neuropsychiatric morbidity in inflammatory bowel disease[J]. Int J Mol Sci, 2022,23(19):11111.
[27]
Haneishi Y, Furuya Y, Hasegawa M, et al. Inflammatory bowel diseases and gut microbiota[J]. Int J Mol Sci, 2023,24(4):3817.
[28]
Wu R, Xiong R, Li Y, et al. Gut microbiome, metabolome, host immunity associated with inflammatory bowel disease and intervention of fecal microbiota transplantation[J]. J Autoimmun, 2023, 26:103062.
[29]
Qiu P, Ishimoto T, Fu L, et al. The gut microbiota in inflammatory bowel disease[J]. Front Cell Infect Microbiol, 2022,12:733992.
[30]
Gubatan J, Holman D R, Puntasecca C J, et al. Antimicrobial peptides and the gut microbiome in inflammatory bowel disease[J]. World J Gastroenterol, 2021, 27(43): 7402-7422.
[31]
Roy S, Dhaneshwar S. Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: current perspectives[J]. World J Gastroenterol, 2023, 29(14): 2078-2100.
[32]
Puvvada S R, Luvsannyam E, Patel D, et al. Probiotics in inflammatory bowel disease: are we back to square one?[J]. Cureus, 2020, 12(9):e10247.
[33]
Thakur V, Singh A, Joshi N, et al. Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis: in-vitro and in-vivo studies[J]. Drug Devel Ind Pharm, 2019, 45(11): 1-39.
[34]
Federici S, Kviatcovsky D, Valdés-Mas R, et al. Microbiome-phage interactions in inflammatory bowel disease[J]. Clin Microbiol Infect, 2023,29(6):682-688.
[35]
Ott S J, Waetzig G H, Rehman A, et al. Efficacy of Sterile Fecal Filtrate Transfer for Treating Patients With Clostridium difficile Infection[J]. Gastroenterology, 2017, 152(4):799-811.e7.
[36]
Naganuma M, Sugimoto S, Mitsuyama K, et al. Efficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis[J]. Gastroenterology, 2018, 154(4): 935-947.
[37]
Ozawa K, Mori D, Hatanaka A, et al. Comparison of the anti-colitis activities of Qing Dai/Indigo Naturalis constituents in mice[J]. J Pharmacol Sci, 2020,142(4):148-156.
[38]
Cao J, Chen M, Xu R, et al. Therapeutic mechanisms of berberine to improve the intestinal barrier function via modulating gut microbiota, TLR4/NF-κB/MTORC pathway and autophagy in cats[J]. Front Microbiol, 2022,13: 961885.
[39]
Liao Z, Xie Y, Zhou B, et al. Berberine ameliorates colonic damage accompanied with the modulation of dysfunctional bacteria and functions in ulcerative colitis rats[J]. Appl Microbiol Biotechnol, 2020,104(4):1737-1749.
[40]
Fei Y, Zhang S, Han S, et al. The Role of Dihydroresveratrol in Enhancing the Synergistic Effect of Ligilactobacillus salivarius Li01 and Resveratrol in Ameliorating Colitis in Mice[J]. Research (Wash D C), 2022, 2022: 9863845.
[41]
Qiao Y, Sun J, Xia S, et al. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity[J]. Food Funct, 2014, 5(6): 1241-1249.
[42]
Xu X, Ocansey D, Pei B, et al. Resveratrol alleviates DSS-induced IBD in mice by regulating the intestinal microbiota-macrophage-arginine metabolism axis[J]. Eur J Med Res, 2023, 28(1): 319.
[43]
Wang P, Gao J, Ke W, et al. Resveratrol reduces obesity in high-fat diet-fed mice via modulating the composition and metabolic function of the gut microbiota[J]. Free Radic Bio Med, 2020,156: 83-98.
[44]
Ren Y, Geng Y, Du Y, et al. Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota[J]. J Nutr Biochem, 2018,57:67-76.
[45]
Candelli M, Franza L, Pignataro G, et al. Interaction between lipopolysaccharide and gut microbiota in inflammatory bowel diseases[J]. Int J Mol Sci, 2021,22(12):6242.
[46]
Chiu H F, Venkatakrishnan K, Golovinskaia O, et al. Gastroprotective Effects of Polyphenols against Various Gastro-Intestinal Disorders: A Mini-Review with Special Focus on Clinical Evidence[J]. Molecules, 2021,26(7):2090.
[47]
Sharma M, Sharma S, Wadhwa J. Improved uptake and therapeutic intervention of curcumin via designing binary -lipid nanoparticulate formulation for oral delivery in inflammatory bowel disorder [J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 45-55.
[48]
Govindaraju R, Karki R, Chandrashekarappa J, et al. Enhanced Water Dispersibility of Curcumin Encapsulated in Alginate-Polysorbate 80 Nano Particles and Bioavailability in Healthy Human Volunteers[J]. Pharm Nanotechnol, 2019,7(1):39-56.
2023, Vol. 34 
